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Noon
1116-1 Preconditioning of the Diabetic Myocardium With Acute 
Metformin Treatment
Aman K. Kakkar, James J. Greer, William H. Bestermann, David J. Lefer, Louisiana State 
University Health Sciences Center, Shreveport, LA
Metformin is a widely used drug for the treatment of type 2 diabetes mellitus. Metformin
activates AMP-activated protein kinase and suppresses lipogenic transcription factors
such as sterol regulatory element binding protein-1 (SREBP-1). We investigated the
effects of acute metformin treatment on the severity of acute myocardial infarction in both
nondiabetic and diabetic mice.
Mice were subjected to left anterior descending coronary artery occlusion (MI) for 30
min. followed by 24 hr. of reperfusion (R). Myocardial area-at-risk (AAR) was determined
with in vivo Evans Blue dye injection and myocardial infarct size (INF) was measured
using TTC staining. db/db diabetic mice and nondiabetic mice (10 weeks of age) were
injected (i.p.) with metformin (0.25 mg/Kg) 18 hours before the onset of MI.
Serum glucose levels were 94±6 mg/dL in nondiabetic mice and 323±16 mg/dL in db/db
diabetic mice (p<0.01 between groups). Metformin treatment did not alter serum glucose
levels at the time of MI. Data for myocardial infarct size in nondiabetic mice are shown in
Figure 1. Acute treatment with metformin significantly (p<0.001) reduced INF/AAR in
nondiabetic mice. Data for myocardial infarct size in db/db diabetic mice treated with met-
formin are shown in Figure 2. Metformin therapy also significantly (p<0.05) attenuated
the extent of myocardial infarction in the db/db diabetic mouse heart.
We conclude that acute metformin treatment protects against myocardial infarction in
both nondiabetic and diabetic mice. 
Noon
1116-2 Delivery of Human Myoblasts Transduced With a Novel 
Bicistronic Vector Carrying Human Vascular Endothelial 
Growth Factor 165 and Angiopoietin-I Forms Mature 
Blood Vessel in the Heart
Lei Ye, Husnain Kh Haider, Ruowen Ge, Peter K. Law, Terrance Chua, Salim Aziz, 
Eugene KW Sim, National University of Singapore, Singapore, Singapore, National 
University Medical Institute, Singapore, Singapore
Backgrounds
We hypothesized that synergy between VEGF165 and angiopoietin-1 (Ang-1) by using a
novel bicistronic vector encoding for two growth factors may lead to better prognosis
when delivered using human myoblasts.
Methods
Human myoblasts carrying lac-z reporter gene were transduced with adenovirus carrying
bicistronic vector encoding for human VEGF165 and Ang-1. The transduced myoblasts
were functionally assessed by immunostaining and RT-PCR. Myocardial infarction model
was created in 17 female swines by coronary artery ligation and grouped as DMEM
injected (group-1 n= 6), myoblast transplanted (group-2 n= 5), and myoblast carrying
bicistronic vector (group-3 n=6). Three weeks later, 5 ml basal DMEM with 3x108 cells or
without cells was injected intramyocardially in and around the infarct and immunosup-
pressed for six weeks using 5mg /kg cyclosporine. The animal was euthanized and the
heart was explanted at 6-12 weeks post cell transplantation and processed for histologi-
cal studies.
Results
High transduction efficiency of myoblasts (>98%) was achieved by multiple transduction
procedure. Myobalsts efficiently secreted VEGF165 and Ang-1 simultaneously as
revealed by dual fluorescent immunostaining and RT-PCR. Extensive survival of the lac-z
positive myoblasts was observed in and around the infarct. Average vascular density at
low power field (x100) by double immunofluorescence staining for vWFactor-VIII and
smooth muscle actin in group-3 (25.07±3.54; 23.71±3.15) was significantly higher than
group-1 (16.0±2.56 p<0.01; 7.87±1.46 p<0.01), group-2 (16.22±3.15 p<0.01; 11.89±3.06
p<0.01) respectively at 6 weeks post treatment. The mature blood vessels count in
group-3 was the highest (94.6%). Regional blood flow (ml/min/g) at 6 weeks improved in
group-3 (3.00± 0.37) significantly as compared to group-1 (1.22± 0.45 p<0.01) and
group-2 (1.12± 0.14 p<0.01). The Ejection fraction in bicistronic group-3 was 43.0
±10.4% which was significantly higher than the control group-1 (34.67±15.37, p<0.05).
Conclusion
Multiple growth factor gene delivery using myoblast as a carrier leads to angiomyogene-
sis with higher percentage of mature blood vessel formation.
Noon
1116-3 Regulation of Intercellular Adhesion Molecule-1 
Transcription in Ischemic-Reperfused Myocardium 
Through STAT3 Activation
Xiao Ping Yang, Anthony DiPaula, Jr., Lewis C. Becker, Johns Hopkins University School 
of Medicine, Baltimore, MD
Intercellular adhesion molecule-1 (ICAM-1) is rapidly upregulated on endothelial cells
(ECs) during ischemia-reperfusion (I-R) and mediates tissue leukocyte accumulation and
subsequent cell injury. Different from other adhesion molecules, the ICAM-1 proximal
promoter contains a STAT1/STAT3 motif (GAS sequence). Because this motif flanks an
SP1 binding site which is very close to the TATA box, it may be important for regulation of
ICAM-1 transcription. To study the role of STAT after myocardial I-R, open chest anesthe-
tized rats underwent anterior descending coronary artery occlusion for 35 min and reper-
fusion (R) for 0, 15, 30, 60, 120, or 240 min. Myocardial samples were rapidly frozen and
analyzed for STAT activation (gel shift and immunoprecipitation), ICAM-1 mRNA level
(real-time R-T PCR) and tissue cytokines (multiplexed sandwich ELISA). STAT was acti-
vated by 15 min R and peaked at 60 min R. Gel supershift assay identified the activated
STAT isoform as STAT3 without STAT1. ICAM-1 mRNA level increased rapidly at 30 min
R, and remained increased through 120 min R. Coimmunoprecipitation of nuclear extract
indicated that STAT3 was bound to SP1, suggesting possible transcriptional cooperativity.
Cytokine assay showed an increase in myocardial IL-6 during I-R. To determine whether
activated STAT3 could regulate ICAM-1 transcription in ECs, cultured human cardiac
microvascular endothelial cells were exposed to IL-6, 40 ng/ml. Phosphorylated STAT3
was identified by immunoprecipitation within 15 min, and ICAM-1 mRNA increased
shortly afterwards at 30 min after IL-6 exposure. Transfection of a GAS decoy oligonucle-
otide to inhibit STAT3 partially blocked IL6-induced ICAM-1 mRNA expression. The
results indicate that STAT3 is activated very quickly in the myocardium following I-R,
interacts with SP1 in the nucleus, and is responsible for rapid upregulation of ICAM-1
transcription.
Noon
1116-4 Consequences of Hemodynamic Instability After 
Carotid Artery Stenting
Alex Abou-Chebl, Rishi Gupta, Christopher T. Bajzer, H. Christian Schumacher, Jay S. 
Yadav, The Cleveland Clinic Foundation, Cleveland, OH
Purpose: To determine if hemodynamic instability (HI) during extracranial carotid artery
stenting (CAS) increases the risk of adverse events.
Background: CAS has been utilized in patients considered at high risk for carotid endar-
terectomy (CEA). HI is a known side effect of carotid sinus stimulation induced by CEA
and CAS. Recent literature suggests that the presence of HI may increase the risk of
adverse cardiovascular events following CEA, however the frequency and consequences
of HI have not been systematically evaluated in a large population of patients undergoing
CAS.
Methods: Patients with HI were identified from the carotid stent registry maintained at
The Cleveland Clinic Foundation. This is a prospectively collected database of all
patients undergoing extracranial CAS for atherosclerotic lesions between 1999-2002. In
addition, the medical records of all CAS patients were retrospectively reviewed to identify
patients with peri-procedural HI who may have been missed by the database. HI was
defined as symptomatic or asymptomatic hypotension (systolic blood pressure < 90) or
braycardia (heart rate < 60). The use of vasopressors or atropine and all peri-procedural
adverse events were study endpoints.
Results: A total of 404 consecutive patients with a mean age of 70.5 ± 9.8 yrs were stud-
ied. Sixty four percent were men. The mean stenosis severity was 85.6 ± 10.1%. Peri-
procedural hypotension occurred in 113 (28%) patients and required vasopressors in 85
% WOMEN IN POSTGRADUATE TRAINING (1992-2001) (rate of change)
Field Minimum % 
women
Maximum % 
women
r (linear 
regression)
Slope P value Cardiol vs 
others (P<0.05=sig)
Cardiol 9.76 15.50 0.94 0.608
 ----
Ob-Gyn
48.10
71.40
0.99 2.36
<0.001
Pediatrics
56.50
65.80
0.98 0.856 0.01
Familiy 
practice 36.20 49.10 0.99 1.23
<0.001
Surgery-
General 14.80 23.70 0.99 0.835
0.024
Neurology
25.60 38.20 0.97 1.34 <0.001
All 
disciplines 28.10 35.62 0.95 0.656 0.608
